BIRC5 and familial pancreatic carcinoma: We next examined expression of survivin message and protein in the pancreatic cancer cell line AsPC-1 in the presence or absence of the deoxycytidine analog gemcitabine, which since 1996 has been approved by the FDA as a first-line treatment for patients with PDAC, and/or ICG-001.